氯喹与羟氯喹对系统性红斑狼疮患者听力影响的研究
本研究为横断面研究,纳入84人(43例SLE患者和41例对照)进行听力学和鼓室压测量。结果显示SLE患者感音神经性听力损失患病率显著高于对照组(23.2% vs. 0,P = .001)。使用与未使用抗疟药患者的纯音平均值相似(8.75 vs. 8.75,P = .63),但在8000 Hz处未使用者表现更差(10.00 vs. 22.50,P = .03)。结论认为SLE患者听力损失患病率高,但不受抗疟药使用影响。
要点
- SLE患者感音神经性听力损失患病率为23.2%,对照组为0(P = .001)。
- 使用与未使用抗疟药的SLE患者纯音平均值无显著差异(8.75 vs. 8.75,P = .63)。
- 在8000 Hz处,未使用抗疟药者听力表现差于使用者(10.00 vs. 22.50,P = .03)。
核心结论
- SLE患者听力损失患病率高,但抗疟药使用未对其产生显著影响。
研究设计与样本
- 横断面研究,纳入84名个体(43例SLE患者和41例对照),进行听力学和鼓室压测量。
主要发现
- SLE患者感音神经性听力损失发生率显著高于对照组(23.2% vs. 0,P = .001)。
- 使用与未使用抗疟药的SLE患者纯音平均值相似(8.75 vs. 8.75,P = .63)。
- 在8000 Hz处,未使用抗疟药者表现差于使用者(10.00 vs. 22.50,P = .03)。
- 所有参与者鼓室压测量均正常。
- 有无听力损失的SLE患者在血清学和临床特征上无显著差异(所有P值不显著)。
临床怎么用
- SLE患者应关注听力损失风险,但抗疟药使用并非听力损失的主要影响因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: Antimalarial drugs (chloroquine and hydroxychloroquine) are widely used for the treatment of systemic lupus erythematosus (SLE). However, these drugs may have side effects such as hearing loss. This study aimed to describe the hearing function in SLE patients using antimalarials. Secondarily, this study aimed to investigate whether SLE causes hearing loss and if there are any serological or clinical aspects of this diseases associated with inner ear damage. STUDY DESIGN: Cross-sectional study. METHODS: This study included 84 individuals (43 SLE patients and 41 controls) with audiometry and tympanometry tests. Epidemiological, clinical, serological, and treatment profiles of SLE patients were extracted from the charts. RESULTS: SLE patients had more sensorineural hearing loss than controls (23.2% vs. 0; P = .001). Pure-tone averages in SLE patients using antimalarials and not using antimalarials were similar (8.75 vs. 8.75; P = .63). At 8,000 Hz, antimalarial dug nonusers performed worse than users (10.00 vs. 22.50; P = .03). Tympanometry was normal in all participants. SLE serological and clinical profiles in patients with and without hearing loss were the same (all P = nonsignificant). CONCLUSIONS: There is a high prevalence of hearing loss in SLE that is not affected by antimalarial drug use. LEVEL OF EVIDENCE: 3b Laryngoscope, 131:E957-E960, 2021.
引用
- Polanski JF, Tanaka EA, Barros H, et al. Chloroquine, Hydroxychloroquine and Hearing Loss: A Study in Systemic Lupus Erythematosus Patients. Laryngoscope. 2020. PMID: 32603516. doi:10.1002/lary.28873
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。